Conference Coverage
Follistatin, endoglin predict postallogeneic HCT NRM
ORLANDO – Follistatin and endoglin levels at posttransplant day 28 predict 1-year nonrelapse mortality in patients who have undergone...
“And the HCT-CI was developed to predict risk of nonrelapse mortality, but relapse in nonmalignant diseases can often be difficult to define,” she added.
The current findings demonstrate the value of the HCT-CI in nonmalignant diseases, and “offer the potential to intervene with transplantation prior to the onset of comorbidities, or with efforts to prevent comorbidities prior to transplantation,” she said, concluding that “future efforts could focus on further refining pretransplant risk assessment for patients with nonmalignant diseases, especially for patients with hemoglobinopathies and HCT-CI scores of less than 3.”
Dr. Broglie reported having no financial disclosures.
sworcester@frontlinemedcom.com
SOURCE: Broglie L et al. Abstract 16.